| 1992 |
 |
CV Technologies incorporated under the Alberta Business Corporations Act to do contract pharmaceutical research. |
|
| 1995 |
|
CV Technologies began developing its ChemBioPrint® technology. |
|
| 1996 |
|
CV Technologies began Clinical Trials (# 1 & # 2) of COLD-fX® involving the Edmonton Oilers Hockey Club. |
|
CV Technologies began limited test marketing of COLD-fX® and other products in selected health food stores. |
|
Oct 17 – CV Technologies was listed on the Alberta Stock Exchange under the symbol CVQ. |
|
| 1997 |
|
CV Technologies conducted Clinical Trial (# 3) of COLD-fX® involving Edmonton seniors. |
|
CV Technologies conducted Phase I Clinical Trials of REMEMBER-fX®, AD-fX® & PRESSURE-fX®. |
|
| 1999 |
|
May – National Research Council of Canada and AVAC Ltd. each invested $0.5 million to help fund Phase II Clinical Trial of COLD-fX® and development of ChemBioPrint® technology. |
|
Oct 1 – U.S. FDA approved and issued an Investigational New Drug (IND) # for Phase II trials (# 4 & # 5) of COLD-fX® involving seniors at five U.S. nursing homes. |
|
Trial # 4 launched. |
|
Health Canada issued CV Technologies a Drug Identification Number (DIN) for COLD-fX®. |
|
| 2000 |
|
May 12 – U.S. Patent & Trademark Office issued CV Technologies with a patent for its proprietary ChemBioPrint® technology and NURITE-fX®/ REMEMBER-fX® product. |
|
DuPont Consumer Health paid CV Technologies $1 million to conduct a comparison study of 200 natural health products using ChemBioPrint® technology. |
|
CV Technologies launched Trial # 6 of COLD-fX® in a doping study involving high performance athletes at the University of Manitoba. |
|
| 2001 |
| |
|
|
CV Technologies became the first natural health products company to successfully complete a U.S. FDA Phase II IND clinical trial. Results released. |
| |
|
|
| 2002 |
|
U.S. & Australian Patent & Trademark Offices grant patents for both COLD-fX® process & composition. |
|
| 2003 |
|
| 2004 |
|
Jan – Journal of the American Geriatrics Society publishes results of trial involving seniors at five U.S. nursing homes. |
|
Feb 2 - Edmonton’s Chief Medical Officer of Health and an internationally recognized nutritional biochemist from the University of Alberta launched Clinical Trial # 8 of COLD-fX®. |
|
May 7 – Launched REMEMBER-fX® in Canada for memory |
|
improvement and protection of brain cells from degeneration. |
|
July – Don Cherry becomes company celebrity spokesperson. |
|
Aug – International Journal of Sport Nutrition and Exercise Metabolism publishes results of University of Manitoba doping trial. |
|
Sept – CV Technologies reports sales increase of 800% in 2004 over fiscal 2003. |
|
Oct 5 – Edmonton’s Chief Medical Officer of Health and an internationally recognized nutritional biochemist from the University of Alberta release results of Trial # 7 and call them "statistically highly significant." |
|
Oct – Over 4,000 Canadian pharmacies, food and health care stores stock COLD-fX®, almost triple the number over winter of 2003. |
|
Oct – Extensive media coverage of results of Trial # 7 including six TV network newscasts, 20 major dailies and 20 radio stations. |
|
CV Technologies reports first profitable year in company’s history. |
|
| 2005 |
| |
|
|
Mar – McGill University
begins COLD-fX® cancer study. |
|
COLD-fX® to be studied as ‘standard of care’ flu treatment in Canadian nursing homes. |
|
Apr – Q1 & Q2 combined sales of $21 million. |
| Apr – ACNielsen® ranks COLD-fX®
the number one selling cold and flu product
in Canada. |
|
Oct – The Canadian Medical Association Journal publishes results of Trial #7. |
|
Nov – CV Technologies posts
year-end sales of $31.9 million and net profit
of $10.1 million. |
|
Dec – The TSX Venture Exchange
selects CV Technologies as its top performing
company in 2005. |
| |
|
|
| 2006 |
| |
|
|
CV Technologies selected as Marketer of the Year by Marketing magazine. |
|
CV Technologies begins trading on Toronto Stock Exchange (CVQ). |
|
Company President Dr. Jacqueline Shan selected as Chinese Canadian Entrepreneur of the Year. |
|
FDA clears COLD-fX to be sold in the U.S. |
|
Wholly-owned subsidiary COLD-fX Pharmaceuticals (USA) Inc. activated. |
|
Positive results announced from pre-clinical cancer study at McGill University. |
|
Hockey legend Mark Messier signed as Company spokesman. |
|
Gold medal winner for fastest growing small cap company in North America by Nutrition Business Journal. |
|
Construction of $9.5 million office headquarters and research centre announced. |
|
fX Life Sciences International established in Switzerland. |
|
North American partnership announced with the NHL. |
|
COLD-fX launched in the U.S. |
|
COLD-fX clinical trial results selected as one of the world’s top 25 significant advances in dietary supplements research by the U.S. National Institutes of Health (NIH). |
|
Dr. Shan selected as #13 in the Top 100 Canadian Woman Entrepreneurs by Profit magazine. |
|
Dr. Shan inducted into the Canadian Healthcare Marketing Hall of Fame. |
| |
|
|
| 2007 |
| |
|
|
Center for Science in the Public Interest’s review of cold medicines concludes that the studies performed on COLD-fX are promising. |
|
Federal Government grants NPN for COLD-fX: strongest medical recognition to date. |
|
American Botanical Council’s published scientific review concluding COLD-fX has “impressive benefits”. |
|
COLD-fX named #1 Pharmacist Recommended Natural Cold Remedy in Canada by Pharmacy Post magazine. |
|
CV Technologies appoints new Chief Operating Officer. |
|
Alberta’s Capital Health announces stockpiling of COLD-fX as part of influenza pandemic preparedness planning. |
|
COLD-fX included in the 2007 Physicians Desk Reference® - used by most U.S. doctors, hospitals and pharmacies. |
|
Clinical Trail begins at Hackensack University Medical Centre in New Jersey to determine if COLD-fX can improve the immune health of front line medical workers. |
| |
|
|
Legal Terms & Conditions
